Major cytogenetic response was achieved in 50 (65%; cumulative, 75%) patients, including 36 (47%) patients with complete cytogenetic response by 12 months. Median time to major cytogenetic response and complete cytogenetic response were 85 days and 256 days, respectively. Major cytogenetic response and complete cytogenetic response rates were similar between imatinib-resistant and imatinib-intolerant patients, but were higher in patients without BCR-ABL1 mutations. Overall and progression-free survival rates at 12 months were 96.1% and 86.3%, respectively. All newly-occurring or worsening grade 3/4 hematologic abnormalities included thrombocytopenia (24.7%) and anemia (5.2%); grade 3/4 drugrelated nonhematologic adverse events included fatigue (3.9%), asthenia (3.9%), and nausea (2.6%). The most common biochemistry abnormality was hyperbilirubinemia (grade 3/4, 23.4%), and 12 of 18 cases were managed with dose modification. Study findings suggest radotinib is effective and well tolerated in chronic phase-chronic myeloid leukemia patients with resistance and/or intolerance to BCR-ABL1 tyrosine kinase inhibitors and may represent a promising alternative for these patients. (NCT01602952;
Introduction
Chronic myeloid leukemia (CML) is characterized by the presence of the Philadelphia chromosome, which forms as a result of a reciprocal translocation between chromosomes 9 and 22 and leads to production of the BCR-ABL1 fusion protein. 2, 3 The first BCR-ABL1 tyrosine kinase inhibitor, imatinib, has been recommended for the first-line treatment of chronic phase CML and has dramatically improved survival rates since its introduction. 4, 5 Nonetheless, some patients with chronic phase-CML have shown imatinib resistance, in most patients due to mutation in BCR-ABL1 that affects the imatinib binding site. [6] [7] [8] Additionally, some patients have developed intolerance due to adverse events associated with imatinib treatment. [9] [10] [11] In an attempt to overcome imatinib resistance, second-generation tyrosine kinase inhibitors were developed, including dasatinib, nilotinib, bosutinib, and ponatinib. [12] [13] [14] [15] However, the costs of second-generation tyrosine kinase inhibitors may be prohibitive, particularly in emerging regions such as the Asia-Pacific countries, and new, lower cost alternatives are necessary. [16] [17] [18] [19] Radotinib (Supect™; C 27 H 21 F 3 N 8 OHCl, 4-Methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethylphenyl]-3-(4-pyrazin-2-yl-pyrimidin-2-ylamino)-benzamide hydrochloride; IL-YANG Pharm. Co., Ltd., Seoul, Korea) is an oral tyrosine kinase inhibitor. In vitro, radotinib binds BCR-ABL1 and reduces phosphorylation of CrkL, a BCR-ABL1 target protein. 20 Furthermore, preclinical studies demonstrated superiority of radotinib to imatinib in both wild-type and mutant BCR-ABL1 positive CML cell lines.
20
In a phase 1 clinical trial, no dose limiting toxicities were observed with a dose of up to 1,000 mg/day.
21
This study evaluated the efficacy and safety of radotinib in Philadelphia chromosome-positive chronic phase-CML patients with resistance and/or intolerance to prior BCR-ABL1 tyrosine kinase inhibitors (Clinicaltrials.gov identifier: NCT01602952).
Methods
Additional details of the study design and methods can be found in the Supplementary Appendix.
Patients
Eligible patients were at least 18 years of age with Philadelphia chromosome-positive chronic phase-CML and resistance and/or intolerance to imatinib. Patients were also eligible if they were intolerant to dasatinib and/or nilotinib, provided that they were also resistant or intolerant to imatinib. Patients with partial cytogenetic response (PCyR) or T315I mutation at screening were excluded. Intolerance was defined as failure to achieve major cytogenic response (MCyR) and having a grade institutional review boards at each site, and all patients provided informed consent.
Study design
This was a multicenter phase 2 clinical trial conducted at 12 sites in Korea, India, and Thailand; the accrual period was between July 2009 and November 2011. Patients were treated with radotinib 400 mg twice daily based on the results of the phase 1 trial. 21 Dose modification was allowed based on response and adverse event. The primary efficacy endpoint of the study was the rate of MCyR by 12 months.
Secondary endpoints included time to MCyR, duration of response, progression-free survival (PFS), and overall survival (OS). Adverse events were classified according to the Common Terminology Criteria for Adverse Events Version 3.0.
Efficacy assessments
Cytogenetic assessments required the evaluation of at least 20 metaphases. To evaluate molecular response to treatment, real-time quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) was performed to measure BCR-ABL1 transcript copy number in International Scale (IS) units. Major molecular response (MMR) was defined as a BCR-ABL1 transcript level of 0.1% or lower on the IS. The ABL1 kinase domain (region equivalent to amino acids 237-486) of BCR-ABL1 was directly sequenced after nested PCR amplification. Cytogenetic, qRT-PCR, and mutation analysis were performed at baseline, every 3 months, and at treatment failure.
Statistical analysis
Efficacy variables were summarized using descriptive statistics, including response rates with 95%
confidence intervals and Kaplan-Meier curves. Time to MCyR was calculated from the first day of radotinib administration to the date of response. Duration of response was calculated from the first date of response to the first date of confirmed loss of response. Disease progression was defined as progression to the accelerated or blast phase in patients who started the trial while in the chronic phase.
OS was calculated from the first day of treatment to the date of death, and PFS was calculated from the first day of treatment to the date of disease progression or death. The safety analysis population was defined as all patients in the intention-to-treat population who had at least 1 post-baseline safety evaluation.
Results

Patients
A total of 77 patients with a median age of 43 years (range, 22 to 75 years) were enrolled in the study; 65 (84.4%) were imatinib-resistant and 12 (15.6%) were imatinib-intolerant ( 
M351T, E355G).
Other kinase domain abnormalities were detected at baseline in 2 patients (between exons 8 and 9, and deletion of amino acids 363-386).
Patient disposition
As of the data cutoff for this analysis on October 9, 2012, the minimum follow-up was 12 months and the median duration of follow-up was 23.4 months ( thrombocytopenia, 7 including 1 patient with liver enzyme elevation; and liver enzyme elevation, 2), disease progression (n = 8), death (n = 2, sepsis), and other reasons (n = 5).
Efficacy
MCyR was achieved in 50 (cumulative, 75%) patients, including 36 (cumulative, 47%) patients with complete cytogenetic response (CCyR) by 12 months (Figure 1 ). At baseline, 4 of 77 patients were in PCyR, which was among the exclusion criteria for study entry. Therefore, patients in PCyR at baseline were only considered eligible for CCyR and were assessed as not responding if they remained in PCyR.
According to these criteria, 3 patients achieving CCyR were assessed as responding, and 1 patient discontinued prior to assessment. Of the patients who achieved CCyR, 11 (30.5%) achieved major molecular response. The median time to MCyR and CCyR were 85 days and 256 days, respectively. By 24 months, 6 of 50 patients in MCyR lost the response, and the probability of remaining in MCyR was 86.8%. The rates of MCyR, CCyR, and MMR for the overall population and for subgroups of patients according to baseline BCR-ABL1 mutation or kinase domain abnormality are shown in Figure 2 .
Among the 14 patients with known BCR-ABL1 mutation or kinase domain abnormality at baseline, 43%
achieved MCyR and 21% achieved CCyR; MCyR and CCyR rates were higher in patients without mutation.
Among 14 patients with BCR-ABL1 mutation (n = 12) or ABL1 kinase domain abnormalities (n = 2) at baseline, these were no longer detectable after 12 months of treatment in 3 patients (1 patient with baseline M351T point mutation and 2 patients with baseline ABL1 kinase domain abnormalities between exons 8 and 9, del 363-386). On treatment, 6 patients retained their baseline mutation(s) and 4 patients had variable mutation dynamics. On the other hand, 6 of 63 patients without baseline mutation had a newly detectable single mutation (E255V, F317L, T315I, F359V, E459K, and E255V) during treatment.
The 12-month estimated OS and PFS rates were 96.1% and 86.3% respectively (Figure 3 ). The probability of PFS was significantly higher in patients without baseline mutations (P = 0.0397). The PFS rate was higher among patients without a baseline mutation compared with those who had baseline mutations at 12 months (90.3% vs 69.6%; Supplementary Figure S1 ). In total, disease progression or death occurred 9 times: 7 disease progression events (at 0.9, 3.9, 5.2, 6.1, 8.1, 9.4, and 9.8 months) and 2 deaths (at 2.6 and 4 months).
Safety
All newly-occurring or worsening grade 3/4 hematologic abnormalities included thrombocytopenia (24.7%) and anemia (5.2%; Table 3 ). Grade 3/4 drug-related nonhematologic adverse events included fatigue (3.9%), asthenia (3.9%), nausea (2.6%), myalgia (1.3%), rash (1.3%), and pruritus (1.3%). The most common biochemical abnormality was hyperbilirubinemia (all grade, 70.1%; grade 3/4, 23.4%; Table 3 ). Hyperbilirubinemia generally occurred in the early period of treatment and was managed by dose reduction or transient interruption; however, 6 patients permanently discontinued treatment due to hyperbilirubinemia. Overall elevations of alanine transaminase (ALT) and aspartate transaminase (AST)
were observed in 85.7% and 72.7% of patients, respectively. Grade 3/4 ALT and AST abnormalities were experienced by 11.7% and 2.6% of patients, respectively. Hyperglycemia was observed in 68.8% of patients, including 19.5% of patients with grade 3/4 hyperglycemia. One (1.3%) patient developed diabetes during the study, but it was not considered drug-related; 8 (10.4%) patients had a history of diabetes at baseline. However, no patients with diabetes interrupted or discontinued study drug due to aggravation of hyperglycemia or required an increase in treatment for their diabetes. Lipase elevation was observed in 37.7% of patients, including 10.4% of patients with grade 3/4 lipase elevation. Although 7 (9.1%) patients had a lipase abnormality at baseline, symptoms related to pancreatitis were not observed in any patients during the treatment period. The incidence of hematologic or biochemical laboratory abnormalities at baseline and after treatment is shown in Supplementary Table S1 . QT interval prolongation (>30 ms change from baseline) was reported in 6 (7.8%) patients; 5 (6.5%) patients had a QT interval of >450 ms but none had an interval >480 ms. There were 2 deaths during the study, both caused by sepsis. One patient died at 2.6 months with soft tissue cellulitis due to disease progression and 1 patient died at 4 months with febrile neutropenia due to pulmonary fungal infection; these patients had minimal cytogenetic response (66-95%) and no cytogenetic response (>95%), respectively, when they died.
Discussion
Radotinib is a BCR-ABL1 specific second-generation tyrosine kinase inhibitor. According to recently conducted in vitro kinase assays, the IC50 value for radotinib against wild type BCR-ABL1 kinase was 34 nM, which is relatively lower compared with the IC50 levels of c-kit (1,324 nM), PDGFR (PDGFRα, 75.5 nM; PDGFRβ, 130 nM) and src (>2,000 nM). Also, radotinib effectively inhibited the proliferation of common mutant clones of BCR-ABL1, with the exception of T315I. In an off-target kinase assay to assess safety, DDR, EPHB, LYN, and PDGFR kinases were inhibited below the 180 nM level (unpublished data).
20,21
This study was designed to evaluate the efficacy and safety of radotinib in patients with chronic phase-CML after resistance and/or intolerance to BCR-ABL1 tyrosine kinase inhibitors. Based on the analysis of the primary endpoint, a cumulative 75% of patients achieved MCyR by 12 months. Additionally, 47%
of patients achieved CCyR, and 22% of patients with MCyR also achieved MMR. OS and PFS rates at 12 months were 96.1% and 86.3%, respectively, and 9 (11.7%) patients experienced disease progression during treatment at a median follow-up of 23.4 months. In the current study, 5 of 12 (42%) patients having baseline BCR-ABL1 mutations had less sensitive mutation to nilotinib or dasatinib. Among them, 2 patients achieved MCyR, and PFS was higher in patients with no baseline BCR-ABL1 mutations.
Efficacy results from this study of radotinib are comparable, and in some cases favorable, to those observed with other second-generation BCR-ABL1 tyrosine kinase inhibitors used in similar treatment settings. In a phase 2 study of dasatinib in 186 patients with imatinib-resistant or imatinib-intolerant chronic phase-CML, MCyR and CCyR rates at 8 months were 45% and 33%, respectively. 23 A phase 2 study of nilotinib in 280 patients with chronic phase-CML and resistance or intolerance to imatinib reported MCyR and CCyR rates of 48% and 31%, respectively, in patients with ≥ 6 months follow-up or who prematurely discontinued the study. 24 In this study, the rates of MCyR and CCyR with radotinib treatment were similar but slightly higher in imatinib-intolerant patients versus imatinib-resistant patients. In the phase 2 study of nilotinib, MCyR and CCyR rates were also similar but generally higher in imatinib-intolerant patients. MCyR and CCyR rates with dasatinib treatment were also higher in imatinib-intolerant patients. A summary of the efficacy of radotinib, dasatinib, and nilotinib is shown in Supplementary Table S2 .
The rates of MCyR and CCyR observed in this study with radotinib were generally higher than those seen in studies of other tyrosine kinase inhibitors. This difference may be due to the patient population in this study; compared with other studies, patients in this study had a shorter duration of CML, had used lower doses of imatinib prior to study entry, and, taken together, had a smaller proportion of patients with mutation of BCR-ABL1. Moreover, according to European LeukemiaNet 2009 guidelines, 22 11 patients with suboptimal response to imatinib were included in this study; however, these patients would be considered to have treatment failure according to European LeukemiaNet 2013 guidelines. 25 Considering the limitations of this patient population, these data suggest the overall response rate with radotinib is comparable with other 2nd generation tyrosine kinase inhibitors.
Adverse events were generally transient and managed by dose reduction or interruption. Overall adverse events were somewhat different than with other BCR-ABL1 tyrosine kinase inhibitors. For example, the incidence of hematologic adverse events was lower and the incidence of hyperbilirubinemia was higher with radotinib compared with other second-generation BCR-ABL1 tyrosine kinase inhibitors. 23, 24 Moreover, some of the troublesome adverse events associated with other BCR-ABL1 tyrosine kinase inhibitors (eg, fluid retention, pulmonary arterial hypertension, and increased risk of bleeding with dasatinib; vascular events with nilotinib) 23, [26] [27] [28] [29] [30] were not observed with radotinib in the current study.
Although grade 3/4 hyperglycemia and lipase elevation were observed in 19.5% and 10.4% of patients, respectively, the metabolic and vascular complications associated with other BCR-ABL1 tyrosine kinase inhibitors were not observed with radotinib; however, as the duration of follow-up in this study was relatively short, a longer follow-up period will be required to more completely assess additional, possible complications with radotinib treatment. Likewise, while nilotinib has been associated with occasional cases of QT interval prolongation, 24, 31 there were no patients with a QT interval of >480 msec at baseline, and no patients experienced a QT interval of >480 msec with radotinib treatment during this study.
In conclusion, the response to radotinib was rapid, deep, and durable, and it was comparable to that observed in phase 2 trials of other second-generation BCR-ABL1 tyrosine kinase inhibitors. The results of this study suggest that radotinib is effective and well tolerated in chronic phase-CML patients with resistance and/or intolerance to BCR-ABL1 tyrosine kinase inhibitors and may represent a promising alternative treatment for these patients. Moreover, a cost-effective tyrosine kinase inhibitor, which can improve accessibility to the drug and increase compliance and adherence to treatment, may be necessary in emerging regions, such as the Asia-Pacific countries. Disease progression was defined as progression to the accelerated or blast phase in patients who started the trial while in the chronic phase. Includes only those patients for whom death was reported as the primary reason for discontinuation of therapy.
e Dose escalation to radotinib 1,000 mg/day was permitted for lack of efficacy (no CHR by 3 months, no CyR by 6 months, or no MCyR by 12 months, or loss of CHR or CyR).
f Dose interruption was defined as >1 day of interruption regardless of reason. CCyR, complete cytogenetic response; MCyR, major cytogenetic response; MMR, major molecular response. a At baseline, 4 of 77 patients had PCyR, which was among the exclusion criteria for study entry. Therefore, patients with PCyR at baseline were only considered eligible for CCyR and were assessed as not responding if they remained in PCyR. According to these criteria, 3 patients achieving CCyR were assessed as responding. Two patients died due to sepsis during treatment and 1 patient died after discontinuation due to disease progression. 
Supplementary Appendix
Supplementary Methods
Definition of resistance to imatinib
Imatinib resistance was defined as treatment with imatinib ≥400 mg/day, inability to achieve complete hematologic response (CHR) at 3 months or any cytogenetic response at 6 months, and inability to achieve major cytogenetic response (MCyR) at 12 months or complete cytogenetic response (CCyR) at 18 months.
Patients
Patients were required to have a World Health Organization/Eastern Cooperative Oncology Group performance status of 0 to 2, adequate hepatic and renal function, and no interferon, anticancer agent, or radiotherapy treatment within 1 week prior to study drug administration. Other exclusion criteria included: blast phase chronic myelogenous leukemia (CML; patients with accelerated phase CML were enrolled separately in this study; in the current report, only patients with chronic phase-CML were analyzed), central nervous system infiltration, impaired cardiac function (including any of the following: left ventricular ejection fraction <45%, QT interval >480 msec, and myocardial infarction, angina pectoris, or severe cardiovascular disease within 3 months prior to enrollment), and severe gastrointestinal disease that may inhibit drug absorption.
Study design
The dose of radotinib could be increased to 500 mg twice daily in the absence of severe toxicities if at least 1 of the following conditions was met: failure to attain CHR by 3 months, failure to attain any cytogenetic response by 6 months, failure to attain MCyR by 12 months, loss of hematologic or cytogenetic response, or disease progression. If required due to toxicity, up to 2 dose reductions were allowed for a minimum daily dose of 400 mg (200 mg twice daily). Food was prohibited 2 hours before and after study drug administration, with the exception of water.
